Deals channel feed – Endpoints News

Deals channel feed

Boehringer taps Dutch biotech for ALT positive cancer pact exceeding $573M in biobucks

2 months ago

Exclusive: VelaVigo inks another US biotech deal as China drug development scene booms

2 months ago

Sanofi to pay $125M upfront for two immunology drugs from little-known biotech

2 months ago

Ayrmid misses deadline for detailed offer to top private equity bid for bluebird

2 months ago

GeneDx to buy Fabric Genomics for up to $51M

2 months ago

Exclusive: A small biotech will bring Roche's Angelman drug back to life

2 months ago

Merck explores potential of oral peptides in deal with Austrian biotech

2 months ago

What's Pfizer's next move after shelving its oral obesity drug danuglipron?

2 months ago

Tempest seeks strategic alternatives to fund Phase 3 liver cancer trial

3 months ago

Market turmoil is tanking biotech M&A and IPOs. Here's the playbook startups will use to survive

3 months ago

PureTech rejects cash exit proposal from Nordic Capital, investment firm says it won't make an offer

3 months ago

GSK’s newest neuro pact is with ABL Bio, a Sanofi-partnered South Korean biotech

3 months ago

Eli Lilly pays struggling Sangamo $18M upfront to tap gene therapy capsid

3 months ago

F-star management takes company private, two years after $161M cash exit to Sino's invoX

3 months ago

Tang Capital's Concentra nabs a win, making a deal to buy Allakos

3 months ago

New CDMO emerges, acquires cell and gene manufacturer Landmark Bio

3 months ago

Bluebird gets new M&A bid, seeking to top private equity offer

3 months ago

Novo inks second obesity deal of the week, with Lexicon oral drug partnership worth up to $1B

3 months ago

Before Alumis went public via IPO, it tried doing a reverse merger with Acelyrin

3 months ago

Merck KGaA pays Abbisko $85M for full commercial rights to benign tumor drug

3 months ago

Why Miga Health's co-founders decided to quit building

3 months ago

Aurion CEO is out as Alcon takes majority stake in cell therapy startup

3 months ago

WuXi Biologics’ licensing deals help offset Biosecure threat in the US

3 months ago

Merck strikes deal for heart drug, worth up to $2B, with China’s Hengrui

3 months ago

First page Previous page 1 2 345 6 7 Next page Last page